Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1182/blood-2016-02-629063 http://scihub22266oqcxt.onion/10.1182/blood-2016-02-629063 C4929923!4929923!27207800     free     free     free Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Blood 2016 ; 127 (26): 3312-20 Nephropedia Template TP {{tp|p=27207800|t=2016. CD19-targeted CAR T-cell therapeutics for hematologic malignancies: interpreting clinical outcomes to date |pdf=|usr=}}{{27207800}} gab.com Text CD19-targeted CAR T-cell therapeutics for hematologic malignancies: interpreting clinical outcomes to date JO: Blood http://www.kidney.de/pget.php?&tw=1&pmid=27207800 #FOAvip Adoptive transfer of T cells genetically modified to express chimeric antigen receptors (CARs) targeting CD19 has produced impressive results in treating patients with B-cell malignancies. Although these CAR-modified T cells target the same antigen, the designs of CARs vary as well as several key aspects of the clinical trials in which these CARs have been studied. It is unclear whether these differences have any impact on clinical outcome and treatment-related toxicities. Herein, we review clinical results reflecting the investigational use of CD19-targeted CAR T-cell therapeutics in patients with B-cell hematologic malignancies, in light of differences in CAR design and production, and outline the limitations inherent in comparing outcomes between studies. Twit Text FOAVip CD19-targeted CAR T-cell therapeutics for hematologic malignancies: interpreting clinical outcomes to date ????Blood http://www.kidney.de/pget.php?&tw=1&pmid=27207800 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=27207800 #FOAvip English Wikipedia <ref>{{Cite pmid|27207800}}</ref> CD19-targeted CAR T-cell therapeutics for hematologic malignancies: interpreting clinical outcomes to date #MMPMID27207800 Park JH; Geyer MB; Brentjens RJ Blood 2016[Jun]; 127 (26): 3312-20 PMID27207800show ga Adoptive transfer of T cells genetically modified to express chimeric antigen receptors (CARs) targeting CD19 has produced impressive results in treating patients with B-cell malignancies. Although these CAR-modified T cells target the same antigen, the designs of CARs vary as well as several key aspects of the clinical trials in which these CARs have been studied. It is unclear whether these differences have any impact on clinical outcome and treatment-related toxicities. Herein, we review clinical results reflecting the investigational use of CD19-targeted CAR T-cell therapeutics in patients with B-cell hematologic malignancies, in light of differences in CAR design and production, and outline the limitations inherent in comparing outcomes between studies. äCD19-targeted CAR T-cell therapeutics for hematologic malignancies: in(epmc).pdf DeepDyve Pubget Overpricing